Stockscreener 앱 받기
8.63
3.98%
0.33
전일 마감가:
$8.30
열려 있는:
$8.42
하루 거래량:
209.18K
Relative Volume:
0.55
시가총액:
$449.43M
수익:
-
순이익/손실:
$-31.93M
주가수익비율:
-12.03
EPS:
-0.7173
순현금흐름:
$-27.71M
1주 성능:
+14.46%
1개월 성능:
+6.02%
6개월 성능:
+65.33%
1년 성능:
+37.42%
1일 변동 폭
$8.24
$8.67
1주일 범위
$7.58
$8.78
52주 변동 폭
$3.19
$10.42
Diamedica Therapeutics Inc Stock (DMAC) Company Profile
명칭
Diamedica Therapeutics Inc
전화
(763) 496-5454
주소
301 CARLSON PARKWAY, MINNEAPOLIS, MN
Compare DMAC vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DMAC
Diamedica Therapeutics Inc
|
8.63 | 432.24M | 0 | -31.93M | -27.71M | -0.7173 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Diamedica Therapeutics Inc Stock (DMAC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-14 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-10-30 | 개시 | TD Cowen | Buy |
| 2024-10-07 | 개시 | H.C. Wainwright | Buy |
| 2024-04-24 | 재개 | Craig Hallum | Buy |
| 2023-06-22 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-04-09 | 개시 | Oppenheimer | Outperform |
| 2021-02-17 | 개시 | ROTH Capital | Buy |
| 2020-10-30 | 개시 | Guggenheim | Buy |
| 2020-07-08 | 개시 | Maxim Group | Buy |
| 2019-04-30 | 개시 | Dougherty & Company | Buy |
| 2019-03-05 | 개시 | Lake Street | Buy |
모두보기
Diamedica Therapeutics Inc 주식(DMAC)의 최신 뉴스
Swing Trade: Can DiaMedica Therapeutics Inc keep up with sector leadersTrade Signal Summary & Community Supported Trade Ideas - baoquankhu1.vn
Highs Report: How does DiaMedica Therapeutics Inc compare to its peersChart Signals & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
DiaMedica Therapeutics Strengthens Balance Sheet With $12.2 Million Capital Raise While Advancing Preeclampsia Program - Longbridge
Dividend Watch: Can DiaMedica Therapeutics Inc. keep up with sector leaders2025 Breakouts & Breakdowns & Smart Investment Allocation Tips - baoquankhu1.vn
Insiders continue to buy DiaMedica Therapeutics Inc. (NASDAQ:DMAC) and now own 47% shares - simplywall.st
Cantor Fitzgerald Sticks to Its Buy Rating for Diamedica Therapeutics (DMAC) - The Globe and Mail
Cantor Fitzgerald reiterates Overweight rating on DiaMedica stock - Investing.com
Aug Final Week: Whats next for CWAN stockJuly 2025 Update & Daily Volume Surge Trade Alerts - baoquankhu1.vn
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(4) - marketscreener.com
What technical charts say about DiaMedica Therapeutics Inc. stock2025 Volume Leaders & Free Expert Approved Momentum Trade Ideas - bollywoodhelpline.com
Short Interest in DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Declines By 22.8% - MarketBeat
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The AI Journal
DiaMedica Therapeutics raises capital via share offering - MSN
Trading Action: Why DiaMedica Therapeutics Inc. stock is a value investor pickWeekly Profit Analysis & Low Risk Entry Point Tips - Bộ Nội Vụ
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Nasdaq Moves: Is DiaMedica Therapeutics Inc a cyclical or defensive stockMarket Performance Summary & Expert Verified Movement Alerts - baoquankhu1.vn
Panic Selling: Can DiaMedica Therapeutics Inc. stock surprise with earnings upsideQuarterly Portfolio Summary & Safe Entry Momentum Stock Tips - Улправда
DiaMedica Therapeutics (NASDAQ:DMAC) Stock Price Down 2.3%Should You Sell? - MarketBeat
Why DiaMedica Therapeutics Inc. stock is a value investor pickRecession Risk & Daily Technical Forecast Reports - ulpravda.ru
DiaMedica Therapeutics (DMAC) Seen as Strong Performer with Upco - GuruFocus
DiaMedica Therapeutics Inc.Common Stock (NQ: DMAC - FinancialContent
DiaMedica Therapeutics sells 1.5 million shares in $12.2 million block trade By Investing.com - Investing.com Nigeria
DiaMedica Therapeutics Raises Capital via Share Offering - TipRanks
DiaMedica Therapeutics sells 1.5 million shares in $12.2 million block trade - Investing.com
A US$59m Drop in the Market Cap of DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Is Not What Insiders Like to See After Purchasing Shares Recently - 富途牛牛
DiaMedica Therapeutics (DMAC) price target increased by 25.68% to 15.81 - MSN
Can DiaMedica Therapeutics Inc. stock surprise with earnings upsideTrade Analysis Summary & Growth Focused Stock Pick Reports - Улправда
Craig-Hallum Reaffirms Their Buy Rating on Diamedica Therapeutics (DMAC) - The Globe and Mail
DiaMedica Therapeutics provides DM199 update following FDA meeting - MSN
Why DiaMedica Therapeutics Inc. stock attracts high net worth investorsGold Moves & Low Volatility Stock Suggestions - Улправда
Is DiaMedica Therapeutics Inc. stock in correction or buying zone2025 Market Outlook & Free Low Drawdown Momentum Trade Ideas - Улправда
After-Hours Biotech Rally: Inspira, MediciNova, DiaMedica Therapeutics Among Gainers - Nasdaq
DiaMedica (DMAC) Advances with FDA in Preeclampsia Study Plans - GuruFocus
DiaMedica Says FDA Seeks Additional Study Ahead of Pre-IND Submission for Preeclampsia Treatment - marketscreener.com
DiaMedica to conduct additional study for preeclampsia treatment - Investing.com
DiaMedica to conduct additional study for preeclampsia treatment By Investing.com - Investing.com Canada
Diamedica Therapeutics provides DM199 preeclampsia program update - marketscreener.com
DiaMedica Advances DM199 Preeclampsia Program After FDA Pre-IND Meeting - TipRanks
DiaMedica Therapeutics Inc Provides DM199 Preeclampsia Program Update - TradingView — Track All Markets
DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA - The AI Journal
[8-K] DiaMedica Therapeutics Inc. Reports Material Event | DMAC SEC FilingForm 8-K - Stock Titan
Diamedica Therapeutics Inc (DMAC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.24%
0.19%
자본화:
|
볼륨(24시간):